December 29, 2023
Authored and Edited by Daniel F. Klodowski; Audrey J. Parker; Jason E. Stach; Elliot C. Cook
In November, a relatively difficult month for appellants, the Federal Circuit affirmed the PTAB on every issue in 8 (88.89%) cases on appeal from post-grant proceedings, including in one precedential opinion: Medtronic, Inc. v. Teleflex Life Sciences Ltd. (Case No. 22-1721). The Federal Circuit dismissed 1 (11.11%) appeal in its precedential Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC (Case No. 22-1706) decision, which held the appellant lacked standing. The court did not issue any opinions with mixed outcomes (in which at least one issue is affirmed) or any opinions in which every issue was vacated or reversed.
Through November 30, 2023, the Federal Circuit cumulatively decided 1,237 appeals from the PTAB in IPRs, CBMs, and PGRs. While the vast majority of these appeals came from IPR proceedings, the number of PGR appeals has slowly increased over time.
In IPR appeals, the Federal Circuit has cumulatively affirmed the PTAB on every issue in 863 (74.08%) cases and reversed or vacated the PTAB on every issue in 147 (12.62%) cases. A mixed outcome on appeal occurred in 119 (10.21%) cases, and the court dismissed 36 (3.09%) IPR appeals on non-settlement grounds without rendering a decision on the merits.
In PGR appeals, the Federal Circuit cumulatively affirmed the PTAB on every issue in 15 (75%) cases, issued a mixed outcome in 1 (5%) case, and reversed or vacated every issue in 4 (20%) cases. No PGR appeals have been dismissed on the merits.
Taken together, in decisions for IPR, CBM, and PGR appeals, the Federal Circuit affirmed every issue in 916 (74.11%) cases, issued a mixed outcome in 124 (10.03%) cases, reversed or vacated every issue in 156 (12.62%) cases, and dismissed 40 (3.24%) cases.
Of the 1,237 IPR, CBM, and PGR cumulative appeals that it has considered, the Federal Circuit issued Rule 36 affirmances in 527 (42.60%) cases. The court issued written opinions, including affirmances, reversals, dismissals, and mixed decisions, in 710 (57.40%) cases. The ratio of Rule 36 affirmances to written decisions has trended steadily downward over time.
Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in February 2024
April 16, 2024
INCONTESTABLE® Blog
April 4, 2024
INCONTESTABLE® Blog
The Federal Circuit’s Heartfelt Affirmation of Everybody’s Right to Use “Everybody vs. Racism”
March 22, 2024
At the PTAB Blog
Federal Circuit PTAB Appeal Statistics for December 2023 and January 2024
March 8, 2024
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in January 2024
March 7, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.